- Home
- OPAD vs BCAB Comparison
OPAD vs BCAB Comparison
Compare OPAD & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPAD
- BCAB
- Stock Information
- Founded
- OPAD 2015
- BCAB 2007
- Country
- OPAD United States
- BCAB United States
- Employees
- OPAD N/A
- BCAB N/A
- Industry
- OPAD Real Estate
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- OPAD Finance
- BCAB Health Care
- Exchange
- OPAD Nasdaq
- BCAB Nasdaq
- Market Cap
- OPAD 25.3M
- BCAB 22.3M
- IPO Year
- OPAD N/A
- BCAB 2020
- Fundamental
- Price
- OPAD $1.38
- BCAB $0.40
- Analyst Decision
- OPAD Hold
- BCAB Buy
- Analyst Count
- OPAD 5
- BCAB 2
- Target Price
- OPAD $2.38
- BCAB $1.00
- AVG Volume (30 Days)
- OPAD 144.5K
- BCAB 521.0K
- Earning Date
- OPAD 08-04-2025
- BCAB 08-07-2025
- Dividend Yield
- OPAD N/A
- BCAB N/A
- EPS Growth
- OPAD N/A
- BCAB N/A
- EPS
- OPAD N/A
- BCAB N/A
- Revenue
- OPAD $794,159,000.00
- BCAB $11,000,000.00
- Revenue This Year
- OPAD N/A
- BCAB N/A
- Revenue Next Year
- OPAD $40.79
- BCAB N/A
- P/E Ratio
- OPAD N/A
- BCAB N/A
- Revenue Growth
- OPAD N/A
- BCAB N/A
- 52 Week Low
- OPAD $0.91
- BCAB $0.24
- 52 Week High
- OPAD $5.13
- BCAB $2.53
- Technical
- Relative Strength Index (RSI)
- OPAD 70.23
- BCAB 48.90
- Support Level
- OPAD $0.91
- BCAB $0.36
- Resistance Level
- OPAD $1.59
- BCAB $0.42
- Average True Range (ATR)
- OPAD 0.13
- BCAB 0.03
- MACD
- OPAD 0.06
- BCAB 0.00
- Stochastic Oscillator
- OPAD 77.94
- BCAB 55.71
About OPAD Offerpad Solutions Inc.
Offerpad Solutions Inc provides a way to buy and sell a home. It uses technology-enabled solutions to remake the home selling and buying experience by offering customers the convenience, control, and certainty to solve their housing needs. It combines fundamental real estate expertise with the data-driven digital Solutions Center platform to efficiently sell and buy their homes online with streamlined access to other services including mortgage, listing, renovation and buyer representation services.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.